This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Heavy Phenacetin Use and Bladder Cancer in Women Aged 20 to 49 Years

List of authors.
  • Joyce M. Piper, DR.P.H.,
  • James Tonascia, Ph.D.,
  • and Genevieve M. Matanoski, M.D., DR.P.H.

Abstract

We investigated the use of analgesics containing phenacetin or acetaminophen in 173 young women with urinary bladder cancer and 173 matched controls. The cases, who were 20 to 49 years old at the time of diagnosis of cancer, were 6.5 times more likely to report regular use of analgesics containing phenacetin at least one year before diagnosis than were their matched controls (odds ratio, 6.5; 95 per cent confidence interval, 1.5 to 59.2). Among the 15 women (13 cases and 2 controls) reporting regular use of phenacetin-containing drugs, 8 of the cases and 1 of the controls reported daily use for over one year (P = 0.04). Excessive use of analgesics containing acetaminophen was not reported. The increased risk of bladder cancer in young women who regularly used phenacetin-containing products remained present after adjustments for all other identified risk factors. (N Engl J Med 1985; 313:292–5.)

Funding and Disclosures

Based on a thesis submitted by J.M.P. to the Johns Hopkins University School of Hygiene and Public Health in partial fulfillment of the requirements for the degree of Doctor of Public Health.

The opinions in this paper are those of the authors and not necessarily those of the FDA.

We are indebted to Dr. William Burnett and the staff of the New York State Department of Health's Cancer Registry for their assistance in this project.

Author Affiliations

From the Epidemiologic Development Branch, Division of Drug and Biological Product Experience, Center for Drugs and Biologics, Food and Drug Administration, Rockville, Md., and the Departments of Biostatistics and Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Md. Address reprint requests to Dr. Piper at the Epidemiology Branch, HFN-733, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

Print Subscriber? Activate your online access.